Bayer Launches Phase III Trial of Long-Acting IUS for Nonatypical Endometrial Hyperplasia
Bayer Launches Pivotal Phase III SUNFLOWER Trial to Evaluate Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia Bayer, a global pioneer in women’s healthcare, has officially initiated SUNFLOWER (Study of…
Aetna Medicaid Boosts Support to Combat Hunger in Local Communities
Aetna Medicaid Deepens Commitment to Ending Hunger with $500,000 Investment in Community Food Organizations Nationwide In a powerful demonstration of its ongoing dedication to community health and well-being, Aetna Medicaid—part…
FDA Grants Priority Review to Baxdrostat New Drug Application for Hard-to-Control Hypertension in the U.S.
FDA Grants Priority Review to AstraZeneca’s Baxdrostat for Hard-to-Control Hypertension—A Potential First-in-Class Therapy In a significant milestone for cardiovascular innovation, the U.S. Food and Drug Administration (FDA) has accepted AstraZeneca’s…
Roche Gets FDA Clearance and CE Mark for First POC Test to Diagnose Whooping Cough
Roche Launches Groundbreaking 15-Minute Point-of-Care Test for Whooping Cough and Other Bordetella Infections, Receiving FDA Clearance, CLIA Waiver, and CE Mark Roche has announced U.S. Food and Drug Administration (FDA)…
Sarah Cannon to Present Blood Cancer & Disorder Advances at 2025 ASH Meeting
SCRI Unveils Groundbreaking Blood Cancer and Blood Disorder Research Through 100 Abstracts at 2025 ASH Annual Meeting In a historic showing that underscores its growing prominence in hematology research, the…
EU Approves Johnson & Johnson’s IMAAVY® (nipocalimab) for Broad gMG Patients, Enabling Long-Term Disease Control
Johnson & Johnson Secures European Commission Approval for IMAAVY® (nipocalimab)—A Groundbreaking FcRn Blocker for Generalised Myasthenia Gravis In a landmark development for the treatment of generalized myasthenia gravis (gMG), Johnson…
Strand Therapeutics Welcomes Jeb Keiper to Its Board of Directors
Strand Therapeutics Strengthens Strategic Leadership with Appointment of Industry Veteran Jeb Keiper to Board of Directors Strand Therapeutics, a pioneering biotechnology company at the forefront of programmable mRNA therapeutics, has…
Latus Bio Receives IND Clearance and Key FDA Designations for LTS-101 in CLN2 Disease
Latus Bio Achieves Major Regulatory Milestone with IND Clearance and Triple FDA Designations for LTS-101 in CLN2 Disease Latus Bio, Inc., a clinical-stage biotechnology company at the forefront of adeno-associated…
AdvanCell Launches Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer
AdvanCell Launches Pivotal Phase 2 Expansion Trial of ADVC001, a First-in-Class Targeted Alpha Therapy for Metastatic Prostate Cancer AdvanCell, a clinical-stage radiopharmaceutical company at the forefront of developing next-generation targeted…
Samsung Bioepis Introduces Denosumab Biosimilars OBODENCE™ and XBRYK™ to European Market
Samsung Bioepis Launches Denosumab Biosimilars OBODENCE™ and XBRYK™ in Europe to Improve Access and Patient Outcomes Samsung Bioepis Co., Ltd., a global biopharmaceutical company recognized for its innovative work in…
Janux Reports Promising Phase 1 Results for JANX007 in mCRPC
Janux Therapeutics Reports Encouraging Interim Phase 1 Data for JANX007 in mCRPC, Highlighting Strong Efficacy and Manageable Safety Profile Janux Therapeutics, Inc. a clinical-stage biopharmaceutical company pioneering novel immunotherapies through…
AltPep Shows SOBIN-AD Peptide Improves Alzheimer’s Behavior in Preclinical Study at CTAD 2025
AltPep Corporation Presents New Preclinical Data Demonstrating SOBIN-AD Peptide Improves Cognition in Early and Symptomatic Alzheimer’s Disease Models at CTAD 2025 AltPep Corporation, a privately held biotechnology company dedicated to…